NextCure (NXTC) Competitor Comparison
We are evaluating the key criteria listed to compare NextCure (NXTC) against its competitors in the Biotechnology industry.
Market Capitalization
302 / 368Gross Profits
201 / 278Total Revenue
0 / 300EBITDA
160 / 337Free Cashflow
172 / 352Quick Ratio
34 / 357Earnings per Share
216 / 359Dividend yield
0 / 6Total Cash
203 / 358Performance 3 years
232 / 368Performance 5 years
332 / 368Performance 10 years
256 / 368Linearity 3 years
202 / 368Linearity 5 years
298 / 368Linearity 10 years
171 / 368Total Rank
41 / 368Dividend Rank
216 / 368Valuation Rank
7 / 368Piotroski Rank
89 / 368Muliplier Rank
11 / 368EBITDA - NXTC ranking 160 / 337
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.